Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Inmed Pharmaceuticals Inc
(NQ:
INM
)
0.3142
-0.0407 (-11.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Inmed Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
Next >
InMed Pharmaceuticals Is Commercializing The Development Of Rare Cannabinoids For The Wellness Market
May 17, 2022
Upon its acquisition of BayMedica LLC last year, InMed Pharmaceuticals Inc. (Nasdaq: INM) made the executive decision to forge a new path alongside its traditional domain in pharmaceutical drug...
Via
Benzinga
InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition
May 13, 2022
InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the...
Via
Benzinga
InMed Commercializes Rare Cannabinoids For Health And Wellness Market
May 09, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
May 03, 2022
It's time for another dive into the biggest pre-market stock movers for today as we prepare for a busy day of trading on Tuesday!
Via
InvestorPlace
InMed Pharmaceuticals' Issues Annual Shareholder Letter
January 05, 2022
InMed Pharmaceuticals (NASDAQ:
Via
Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
May 03, 2022
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and MicroSafe Group DMCC reported EPA approval for...
Via
Benzinga
66 Biggest Movers From Yesterday
May 03, 2022
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged...
Via
Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
April 26, 2022
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:...
Via
Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Announces Expansion Of Rare Cannabinoid Portfolio
April 22, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Announces Participation In Upcoming Conferences
April 20, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
InMed Pharmaceuticals Committed To Growing Market Reach, Product Portfolio
March 28, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
InMed Pharmaceuticals Makes Changes In Management
March 18, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
63 Biggest Movers From Yesterday
March 25, 2022
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet...
Via
Benzinga
InMed Launching Additional Rare Cannabinoids In Response To Demand
March 17, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
InMed Pharmaceuticals Expanding Portfolio In Rare Cannabinoid Market
March 04, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
March 02, 2022
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...
Via
Benzinga
InMed's Evolution To Commercial Sales Featured In Research Report
February 17, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
InMed Names BayMedica VP Of Sales, Releases Q2 2022 Report
February 16, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a...
Via
Benzinga
InMed Positioned To Offer Rare Cannabinoid Manufacturing Technologies
February 15, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
InMed Pharmaceuticals To Release Q2 Financial Report, Update
February 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a...
Via
Benzinga
InMed Pharmaceuticals Strengthens Leading Role In Rare Cannabinoid Market
February 04, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cannabicitran is the first of four new rare cannabinoids InMed...
Via
Benzinga
InMed Pharmaceuticals Defining Value Of Rare Cannabinoids In Pharma Space
February 03, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
InMed Pharmaceuticals Expands Rare Cannabinoid Product Portfolio to Launch CBT
January 20, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a...
Via
Benzinga
4 Penny Stocks Insiders Are Buying
January 07, 2022
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste...
Via
Benzinga
InMed Pharmaceuticals to Present at Tribe Public's Webinar Event
December 30, 2021
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and...
Via
Benzinga
InMed Pharmaceuticals Announces Publication of Article on CBN as Possible Glaucoma Treatment
December 20, 2021
InMed Pharmaceuticals (NASDAQ:
Via
Benzinga
InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
December 10, 2021
InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following...
Via
Benzinga
InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs
December 01, 2021
InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update
November 29, 2021
InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.